Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated medicine strategies to optimize clopidogrel and aspirin therapy using genotype-guided treatment
ChiCTR-TRC-13003596Phase 3Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Aug 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clopidogrel, aspirin and warfarin in coronary thrombosis and Atrial fibrillation (AFib) (5 arms), sponsored by Fujian Provincial Hospital. Primary endpoints: CYP2C19 genotype, Platelet aggregation and 3 more. Started Aug 2013; status: recruiting.
02
Drugs
clopidogrelaspirinwarfarin
03
Conditions
coronary thrombosisAtrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR-TRC-13003596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003596.